Wendell Amy McBride 4

What Happened

• Amy McBride, a member of Axogen, Inc.'s Board of Directors, had restricted stock units convert/vest into common stock on June 19, 2026. The Form 4 shows two derivative conversions (code M), each for 14,150 shares, for a total of 28,300 shares acquired at $0.00 per share (no cash paid).
• The filing indicates these were vested restricted stock units (RSUs) rather than open‑market purchases or sales, so this is a routine equity compensation event rather than an actionable buy or sell.

Key Details

• Transaction date: June 19, 2026. Report filed: June 23, 2026 (appears timely under the Form 4 two-business‑day rule).
• Price: $0.00 per share (RSU vesting/conversion; no cash exchanged).
• Shares acquired: 14,150 + 14,150 = 28,300 shares total.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes from the filing:
  • F1: The reported amounts reflect RSUs that vested on June 19, 2026.
  • F2: Each RSU represents a contingent right to one share of common stock.
  • F3: The RSU award was the annual director equity grant; the number of shares was based on a $150,000 valuation at grant date and vested on the one‑year anniversary.
• Transaction code: M = exercise or conversion of a derivative security (in this case, RSU vesting/conversion).

Context

• This was a compensation-related vesting of RSUs, not a market purchase or sale. Such awards are routine for directors and do not by themselves indicate insider buying or selling intent.
• The filing shows no immediate sale (cashless exercise) or withholding details; no proceeds or sale activity are reported.